RF vs XERS · rev $1.75B vs rev $175.2M
RF (RF) versus Xeris Pharmaceuticals Inc (XERS) — a side-by-side from cached financials, not a winner call.
RF (RF) common stock.
Xeris Pharmaceuticals Inc (XERS) is a biotechnology company listed on US.
Latest reported RF revenue for 2026-06-30 was $1.75B. Net income was $570.0M. Revenue was up 2.7% from 2026-03-31 to 2026-06-30. RF currently screens at market cap $0.
Latest reported XERS revenue for 2026-06-30 was $175.2M. Net income was -$28.9M. XERS currently screens at market cap $760.7M.
RF currently screens at market cap $0. XERS currently screens at market cap $760.7M.
Not investment advice. Open the RF and XERS stock pages for the full models.
Not investment advice.